80791-78-2

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dihydroxy-3,5-dibromopyridine is used as a potential pharmaceutical candidate for the development of new drugs and treatments for various diseases. Its antioxidant properties make it a promising compound for research and development in this field.
Used in Agrochemical Industry:
In the agrochemical industry, 2,4-Dihydroxy-3,5-dibromopyridine is used as a potential component in the development of new agrochemical products. Its unique structure and properties may contribute to the creation of innovative solutions for agricultural applications.
Used in Materials Science:
2,4-Dihydroxy-3,5-dibromopyridine is used as a potential building block for the development of new materials with specific properties. Its bromine atoms make it a candidate for the creation of materials with flame retardancy or controlled release applications.
Further research is needed to fully understand the potential applications and properties of 2,4-dihydroxy-3,5-dibromopyridine, as its unique structure and properties may lead to innovative solutions in various industries.

Upstream product

• 626-03-9 3-deazauracil 
• 626-03-9 4-hydroxy-2-pyridone 

Downstream Products

• 856857-52-8 2,4,6-tribromopyridine 
• 80791-79-3 5-bromo-pyridine-2,4-diol 
• 96245-97-5 3-bromo-2,4-dihydroxypyridine 
• 80791-85-1 1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-4-hydroxy-2-pyridinone 
• 80791-79-3 5-bromo-4-hydroxy-2-pyridinone 
• 144584-32-7 3-bromo-2,4-dichloro-pyridine 
• 221241-37-8 2,5-dibromo-[4]pyridylamine 

Relevant academic research and scientific papers

Biological evaluation of pyridone alkaloids on the endocannabinoid system

Naturally occurring pyridone alkaloids as well as synthetic derivatives were previously shown to induce neurite outgrowth. However, the molecular basis for this biological effect remains poorly understood. In this work, we have prepared new pyridones, and tested the effect of thirteen 4-hydroxy-2-pyridone derivatives on the components of the endocannabinoid system. Investigation of binding affinities towards CB1 and CB2 receptors led to the identification of a compound binding selectively to CB1 (12). Compound 12 and a closely related derivative (11) also inhibited anandamide (AEA) hydrolysis by fatty acid amide hydrolase. Interestingly, none of the compounds tested showed any effect on 2-AG hydrolysis by monoacylglycerol lipase at 10 μM. Assessment of AEA uptake did, however, lead to the identification of four inhibitors with IC50 values in the submicromolar range and high selectivity over the other components of the endocannabinoid system.

Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways

Identification and validation of the targets of bioactive small molecules identified in cell-based screening is challenging and often meets with failure, calling for the development of new methodology. We demonstrate that a combination of chemical proteom

PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

Total synthesis of pyridovericin

The total synthesis of the naturally occurring kinase inhibitor pyridovericin 1 is reported. A flexible and efficient synthesis has been accomplished in good yield from readily available 2,4-dihydroxypyridine. Pyridovericin is a key intermediate in our pr

Total synthesis of pyridovericin: studies toward the biomimetic synthesis of pyridomacrolidin.

[reaction: see text] The total synthesis of the novel metabolite pyridovericin 1 is reported. The synthesis of this key intermediate in our proposed biomimetic synthesis of pyridomacrolidin 2 has been accomplished in good yield from readily available 2,4-dihydroxypyridine.